July 11, 2008 - AngioScore Inc. today announced the launch of new longer and larger AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD).

The new devices have FDA 510(k) clearance to market for the dilatation of lesions in the iliac, femoral, ilio-femoral, popliteal, and infra popliteal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. The PTA catheter is not labeled for use in the coronary or neuro-vasculature.

AngioScore Inc. has introduced longer and larger AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD).

Bioheart Inc. offers the Bioheart 3370 Heart Failure Monitor, an interactive and simple-to-use at-home device designed to better monitor patients outside hospitals who are suffering from heart failure. The device, manufactured by RTX Healthcare A/S of Denmark, has FDA 510(k) market clearance and CE Mark in Europe.

stents, des vs bare metal stents, stent technology, what is a stent, bioresorbable vs metallic stents

(Editor's note: this article was updated in March 2017 with links at the bottom to more current stent technology articles from 2016 and 2017)

There are great comeback stories throughout sports history. One of the more recent ones was when Bo Jackson, who played NFL football and MLB baseball, had hip-replacement surgery, yet came back to play two more years of professional baseball on an artificial hip. This feat was recognized when Jackson won the Major League Baseball Comeback Player of the Year Award in 1993.

Safe delivery of the balloon or stent through fragile vasculature during percutaneous transluminal coronary angioplasty (PTCA) procedures is an important criterion for successful patient outcomes.

Preliminary results of a multicenter study show that the use of tiny clips to repair the mitral valve may someday eliminate the need for open-heart surgery for most sufferers of mitral regurgitation (MR).

What makes cardiologists more capable of reading cardiac imaging exams than other physicians such as radiologists, who are specifically trained to read coronary CT, cardiac MRI, PET and so on?

The only safe assumption to make about today’s current gold standard imaging modality used to identify and evaluate atheromatous plaque in the peripheral arteries is that there is not one gold standard. To locate and evaluate these plaques that cause peripheral vascular disease (PVD), physicians have multiple tried-and-true imaging tests at their disposal.

Physicians recognize the importance of ventricular assist devices (VADs) every time a congestive heart failure (CHF) patient awaiting transplantation gets a therapeutic bridge. But VADs are playing an increasingly critical role not just in improving patient outcomes but also in cutting overall healthcare costs.

With the recent introduction of new VAD models and upgrades in the U.S., in addition to new devices entering final clinical trials this year, these technological innovations promise to further bridge the gaps in both patient care and healthy healthcare spend.

Cardiology fellows are expanding their knowledge in cardiovascular imaging. Not only do virtually all cardiology fellows get Level 2 training in echocardiography and many in nuclear cardiology but now, an increasing number of fellows are training in cardiac MR and cardiac CT.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now